Investing in the entrepreneurs enabling millions to find freedom, fulfillment and happiness

Our approach

We are a fund dedicated to the mind: our mental and neurological health. We invest in brilliant founders solving humanity’s most prevalent and damaging problems. Proudly part of Christian Angermayer’s Apeiron Investment Group.

Our focus

Brain-computer interfaces

A proven technology with an astonishing array of applications. The world’s most advanced devices are now moving out of the lab and into the clinic.

Personalisation

The mind is complex, and each of us is unique. We can finally move beyond one-size-fits-all, thanks to new measurement tools, advanced analytics and AI.

New pharmacology

From psychedelics to gene therapy, the field for drug discovery and development has never been richer with innovation.

New modalities

TMS, chatbots, neurofeedback and beyond… new technologies are finally coming of age and unlocking effective ways to heal and enhance ourselves.

Brain-computer interfaces

A proven technology with an astonishing array of applications. The world’s most advanced devices are now moving out of the lab and into the clinic.

FIGURE // 39100 Ⓐdf4q663u

Personalisation

The mind is complex, and each of us is unique. We can finally move beyond one-size-fits-all, thanks to new measurement tools, advanced analytics and AI.

FIGURE // 39100 Ⓐdf4q663u

New pharmacology

From psychedelics to gene therapy, the field for drug discovery and development has never been richer with innovation.

FIGURE // 39100 Ⓐdf4q663u

New modalities

TMS, chatbots, neurofeedback and beyond… new technologies are finally coming of age and unlocking effective ways to heal and enhance ourselves.

FIGURE // 39100 Ⓐdf4q663u

Our portfolio

We are a venture capital fund dedicated to mental & neurological health.

Direct brain communication via hardware-agnostic software

Learn more

Modified psychedelic compounds to remove hallucinations

Learn more

Precision psychiatry for mental health conditions

Learn more

Subcranial BCI to help patients move, talk, hear & see again

Learn more

Synbio applications across pharmacology, food & materials

Learn more

Scalable digital platform for cutting-edge clinics

Learn more

Creators of the Stentrode: BCI without invasive surgery

Learn more

Immersive, meditative experiences delivered via XR

Learn more

Fully passive digital phenotyping for your smartphone

Learn more

Sleep training for children, with 100% guarantee

Learn more

Drug discovery platform focussed on psychoactive plants

Precision psychiatry based on multimodal biomarker data

Learn more

Biotech platform with patented libraries of psychedelic NCEs

Learn more

Creators of the Galea, a multimodal BCI headset

Learn more

Powerful biomarker platform built on optical tweezer tech

Learn more

Drug discovery AI platform, starting in Parkinson’s Disease

Learn more

Highly personalised online psychiatry and prescriptions

Learn more

Powerful computational neuroscience, via your smartphone

Learn more

Novel therapeutics inspired by kanna

Learn more

Precision treatment via micro-robot delivery

Learn more

DMT based therapies for the treatment of depression

Learn more

Breakthrough non-invasive neuromodulation, in stealth mode

Next-gen neural engineering via high-res surface electrodes

Learn more
“Science progresses best when observations force us to alter our preconceptions.”

Vera Rubin, Astronomer

Meet our team

Co-founder & General Partner

Christian Angermayer

LinkedIn Twitter

Co-founder & General Partner

Max de Vere

LinkedIn Twitter

Co-founder & General Partner

Jan Hardorp

LinkedIn

Investment Associate

Joao Barbosa da Silva

LinkedIn

ON OUR MINDS

Feb. 06, 2023

Alto Neuroscience Announces $60 Million in Additional Financing

Read more

Feb. 23, 2022

Thought-To-Text Typing Hits 90 Characters/Minute With 94% Accuracy

Read more

Nov. 17, 2022

Blackrock Neurotech Reveals Latest Innovation in Next-Gen BCI

Read more
News & insights hub

OUR CLOSE FRIENDS
& PARTNERS